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Chi Van Dang1* and Michael Pollak2*The identification of oncogenic driver mutations of
many cancers by deep sequencing is validating the onco-
gene versus tumor suppressor paradigm of tumorige-
nesis. At the same time, there is a profound resurgence
of interest in metabolism in the context of neoplasia,
both at the whole-organism level with respect to the in-
fluence of caloric intake on cancer behavior, and at the
cellular level, with respect to possible therapeutic ex-
ploitation of differences between the metabolism of nor-
mal and cancer cells. The rapid expansion of research
on metabolic aspects of neoplasia has improved our
understanding of how oncogenes and tumor suppressors
are linked to altered cancer cell metabolism, and how
altered metabolism, in turn, affect the cancer epigenome.
Enzymes of key metabolic pathways are mutated in specific
types of cancers, linking oncogenic alterations to perturbed
metabolism. Newly identified metabolic pathways have also
emerged as the flexibility of re-wired cancer cell metabo-
lism is appreciated. Much of this development has been
enabled by better tools to study the genome as well as cel-
lular metabolism.
At the organismal level, the clinical association of
obesity with increased cancer risk, the classic observa-
tions that caloric restriction can inhibit carcinogenesis in
rodent models, and experimental models that suggest
that the behavior of a subset of cancers is influenced by
drugs such as metformin, that may act at least in part by
perturbing whole organism energy metabolism, further
tie altered metabolic states with tumorigenesis and can-
cer progression. Improvements in metabolic imaging
have also provided new glimpses of in vivo real-time
metabolic changes. Both hyperpolarized 13C MRI and
new positron emission tomography (PET) radiolabeled
ligands provide remarkable insights into tumor metabo-
lism in vivo. The journal Cancer & Metabolism provides
a timely forum to report progress in cancer research
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Why Cancer & Metabolism now? It is a journal over-
seen by practicing scientists for scientists, to offer a
rapid means to communicate research findings in this
booming field. The journal aims for rapid turn around
and minimal revisions limited only to those that may be
required to substantively support the major conclusions
drawn in the title and abstract of the paper. The journal
will also provide timely critical reviews in areas of this
rapidly changing field. All articles will be published on-
line and open access soon after acceptance, thus provid-
ing a rapidly growing forum for significant research. A
brief history of the field below will underscore what has
brought us to this point, as well as our predictions for
this exciting, turbulent area of research.
The discoveries of major metabolic pathways decades
ago by notables, such as Krebs, Warburg, Embden,
Myerhof, Kennedy, and others, laid the foundation for
the use of experimental methods to study the metabol-
ism of cancer. Otto Warburg has remained to date as
the most prominent contributor to our early under-
standing of cancer metabolism, with aerobic glycolysis
or the Warburg effect recognized as a hallmark of can-
cer. This apparent reversion of cancer cells to a primitive
form of energetic metabolism, as compared to oxidative
phosphorylation, was thought to contribute directly to
the development of cancer well before the identification
of oncogenes and tumor suppressors. While recent data
require some refinement of Warburg’s conclusions, the
impact of his pioneering work remains considerable. It is
instructive to recognize that Warburg detected meta-
bolic features of neoplastic cells as distinct from
untransformed cells with relatively simple methods, well
before the complexities of oncogenic signaling networks
had been recognized.
The discovery of cancer genes took the center stage of
cancer research for several decades, providing significant
insight into the development of cancer. However, beyond
the molecular switches controlled by genes that turn
growth and proliferative programs on and off, little was
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balanced assembly of new cellular components of the
growing cell. In retrospect, it is unsurprising that many
cancer genes are directly connected with the regulation
of cell metabolism in order that adequate amounts of
ATP, carbon skeletons and nitrogen are acquired and
channeled into macromolecular synthesis. Importantly,
while Warburg focused on glucose metabolism, we now
know that the cancer cell utilizes a variety of nutrient
sources, not only by transport of raw nutrients such as
glucose and glutamine into the cells, but also by resorting
to autophagy and macropinocytosis to eat themselves or
the surrounding nutrient-rich circulating proteins and
lipids.
As with any rapidly emerging field, we anticipate the
leading edge of findings to be turbulent, provocative,
and controversial, only to settle in the calmer wake of
established facts that endure the test of time. Hence,
Cancer & Metabolism expects to publish provocative
and controversial findings as long as the scientific merit
of the work holds up to fair peer review.
Peeking into the future, we expect that hypotheses
concerning the efficacy of “metabolic therapies”, such as
the use of biguanides (to inhibit mitochondrial Complex
I and activate AMPK) or chloroquine (to inhibit autop-
hagy), and others will be tested in the clinic, and that
results will stimulate new lines of investigation that will
build on early hypotheses. Perhaps mechanisms linking
obesity to cancer risk will rest on new activities of adipo-
kines whose altered levels could directly affect cancer
cells. Insights into how the circadian regulation of meta-
bolism could affect tumorigenesis or could be exploited
for therapy may be forthcoming. Although caloric restric-
tion as it relates to longevity may be controversial, as the
result of a recent study in monkeys shows, its role in can-
cer development may be further revealed not only through
genetically engineered mouse models of cancers, but also
through more sophisticated population studies where
metabolic characteristics are quantified. The role of mito-
phagy (the removal of mitochondria via the autophagic
machinery, particularly during nutrient deprivation) may
prove to be important to cancer development, and involve
processes such as increased oxidative stress attributable to
failed mitophagy.
Hypoxia, which is prevalent in cancers, may be
exploited for therapeutic purposes through direct effective
targeting of HIF or its targets. Drug candidates that target
specific enzymes, such as fatty acid synthase, glutaminase,
lactate dehydrogenase, pyruvate dehydrogenase kinase 1,
pyruvate kinase, or those targeting metabolic transporters,
such as MCT1 and GLUT1, may appear in the next few
years from the efforts of many companies and academic
laboratories. Evaluation of these agents may require com-
panion diagnostics, and may offer important opportunitiesfor synthetic lethality in combination with other drugs.
The complexity of the tumor microenvironment will re-
veal not only cell intrinsic tumor heterogeneity but also
the complex features of obligate dependency of metabolic
programs of stromal cells on those of the cancer cells and
vice versa.
The rapid pace of discovery in this field will benefit from
an open access forum such as Cancer & Metabolism to
disseminate information and to promote an area of inves-
tigation that holds promise for both curiosity driven basic
research and clinically directed research as we seek to
improve the diagnosis and therapy of cancer. The time is
now, and the place to publish a wide spectrum of work on
cancer metabolism is Cancer & Metabolism. We look
forward to many exciting volumes after this inaugural
issue, which provides examples of the promising research
and excitement in the field.
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